{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:05:13Z","timestamp":1790928313241,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"DOI":"10.1093\/aje\/kwx253","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T15:10:46Z","timestamp":1497453046000},"page":"298-305","source":"Crossref","is-referenced-by-count":26,"title":["Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States"],"prefix":"10.1093","volume":"187","author":[{"given":"Susan","family":"Hariri","sequence":"first","affiliation":[{"name":"Division of STD Prevention, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6009-8367","authenticated-orcid":false,"given":"Megan S","family":"Schuler","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L","family":"Naleway","sequence":"additional","affiliation":[{"name":"Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F","family":"Daley","sequence":"additional","affiliation":[{"name":"Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado"},{"name":"Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Weinmann","sequence":"additional","affiliation":[{"name":"Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Crane","sequence":"additional","affiliation":[{"name":"Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia R","family":"Newcomer","sequence":"additional","affiliation":[{"name":"Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Tolsma","sequence":"additional","affiliation":[{"name":"Center for Clinical and Outcomes Research, Kaiser Permanente Georgia, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri E","family":"Markowitz","sequence":"additional","affiliation":[{"name":"Division of STD Prevention, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,21]]},"reference":[{"issue":"19","key":"key\n\t\t\t\t20180313123355_kwx253C1","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"19","key":"key\n\t\t\t\t20180313123355_kwx253C2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"N Engl J Med"},{"issue":"9580","key":"key\n\t\t\t\t20180313123355_kwx253C3","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180313123355_kwx253C4","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"FUTURE I\/II Study Group","year":"2010","journal-title":"BMJ"},{"issue":"5","key":"key\n\t\t\t\t20180313123355_kwx253C5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"key\n\t\t\t\t20180313123355_kwx253C6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","article-title":"Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women","volume":"85","author":"Fairley","year":"2009","journal-title":"Sex Transm Infect"},{"key":"key\n\t\t\t\t20180313123355_kwx253C7","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"BMJ"},{"issue":"9706","key":"key\n\t\t\t\t20180313123355_kwx253C8","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"Romanowski","year":"2009","journal-title":"Lancet"},{"issue":"17","key":"key\n\t\t\t\t20180313123355_kwx253C9","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"issue":"22","key":"key\n\t\t\t\t20180313123355_kwx253C10","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"issue":"36","key":"key\n\t\t\t\t20180313123355_kwx253C11","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1016\/j.vaccine.2014.12.002","article-title":"Human papillomavirus vaccines: WHO position paper, October 2014\u2014recommendations","volume":"33","year":"2015","journal-title":"Vaccine"},{"issue":"49","key":"key\n\t\t\t\t20180313123355_kwx253C12","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination\u2014updated recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"key\n\t\t\t\t20180313123355_kwx253C13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/jama.2014.95","article-title":"Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma","volume":"311","author":"Herweijer","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"key\n\t\t\t\t20180313123355_kwx253C14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/cid\/civ364","article-title":"Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: a nationwide study of 550,000 young girls","volume":"61","author":"Blomberg","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"7","key":"key\n\t\t\t\t20180313123355_kwx253C15","doi-asserted-by":"crossref","first-page":"e0132404","DOI":"10.1371\/journal.pone.0132404","article-title":"Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study","volume":"10","author":"Dominiak-Felden","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180313123355_kwx253C16","doi-asserted-by":"crossref","first-page":"g1458","DOI":"10.1136\/bmj.g1458","article-title":"Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia","volume":"348","author":"Crowe","year":"2014","journal-title":"BMJ"},{"issue":"9","key":"key\n\t\t\t\t20180313123355_kwx253C17","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/bjc.2014.479","article-title":"Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland","volume":"111","author":"Pollock","year":"2014","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180313123355_kwx253C18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Med"},{"key":"key\n\t\t\t\t20180313123355_kwx253C19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pvr.2015.05.005","article-title":"Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia","volume":"1","author":"Brotherton","year":"2015","journal-title":"Papillomavirus Res"},{"issue":"11","key":"key\n\t\t\t\t20180313123355_kwx253C20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/OLQ.0000000000000186","article-title":"Estimating chlamydia screening coverage: a comparison of self-report and health care effectiveness data and information set measures","volume":"41","author":"Khosropour","year":"2014","journal-title":"Sex Transm Dis"},{"issue":"8","key":"key\n\t\t\t\t20180313123355_kwx253C21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/OLQ.0000000000000154","article-title":"Evaluation of a surveillance case definition for anogenital warts, Kaiser Permanente Northwest","volume":"41","author":"Naleway","year":"2014","journal-title":"Sex Transm Dis"},{"issue":"19","key":"key\n\t\t\t\t20180313123355_kwx253C22","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"issue":"1","key":"key\n\t\t\t\t20180313123355_kwx253C23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"key\n\t\t\t\t20180313123355_kwx253C24","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1586\/14760584.2014.935767","article-title":"Alternative dosage schedules with HPV virus-like particle vaccines","volume":"13","author":"Stanley","year":"2014","journal-title":"Expert Rev Vaccines"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/aje\/article-pdf\/187\/2\/298\/24331285\/kwx253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T12:41:01Z","timestamp":1520944861000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/187\/2\/298\/3883633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,21]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6,21]]},"published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwx253","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2]]},"published":{"date-parts":[[2017,6,21]]}}}